LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

UNH

303.28

-5.72%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

UNH

303.28

-5.72%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

UNH

303.28

-5.72%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

UNH

303.28

-5.72%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

UNH

303.28

-5.72%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

Search

Corvus Pharmaceuticals Inc

Abierto

3.58 -2.72

Resumen

Variación precio

24h

Actual

Mínimo

3.53

Máximo

3.76

Métricas clave

By Trading Economics

Ingresos

28M

-12M

BPA

-0.138

Empleados

31

EBITDA

-851K

-8.1M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+268.23% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.3M

276M

Apertura anterior

6.3

Cierre anterior

3.58

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2025, 20:54 UTC

Adquisiciones, fusiones, absorciones

PNC to Buy Private-Equity Agent Aqueduct Capital

20 may 2025, 20:50 UTC

Ganancias

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 may 2025, 23:48 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 may 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 may 2025, 23:39 UTC

Charlas de Mercado

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 may 2025, 23:08 UTC

Charlas de Mercado

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 may 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 may 2025, 22:44 UTC

Principales Noticias

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- 2nd Update

20 may 2025, 22:20 UTC

Principales Noticias

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 may 2025, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 may 2025, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 may 2025, 22:00 UTC

Ganancias

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 may 2025, 21:44 UTC

Ganancias

James Hardie Industries 4Q Adj EPS 36c >JHX

20 may 2025, 21:44 UTC

Ganancias

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 may 2025, 21:44 UTC

Ganancias

James Hardie Industries 4Q EPS 10c >JHX

20 may 2025, 21:44 UTC

Ganancias

James Hardie Industries 4Q Sales $972M >JHX

20 may 2025, 20:52 UTC

Principales Noticias

Elon Musk to Cut Back Political Spending -- 3rd Update

20 may 2025, 20:52 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 may 2025, 20:52 UTC

Charlas de Mercado

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 may 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 may 2025, 20:28 UTC

Adquisiciones, fusiones, absorciones

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 may 2025, 20:23 UTC

Adquisiciones, fusiones, absorciones

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 may 2025, 20:22 UTC

Ganancias

XP 1Q Adj EPS BRL2.29 >XP

20 may 2025, 20:22 UTC

Ganancias

XP 1Q Rev BRL4.345B >XP

20 may 2025, 20:21 UTC

Adquisiciones, fusiones, absorciones

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 may 2025, 20:20 UTC

Principales Noticias

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 may 2025, 20:19 UTC

Adquisiciones, fusiones, absorciones

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 may 2025, 20:11 UTC

Principales Noticias

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 may 2025, 20:09 UTC

Ganancias

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

Comparación entre iguales

Cambio de precio

Corvus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

268.23% repunte

Estimación a 12 Meses

Media 13.33 USD  268.23%

Máximo 17 USD

Mínimo 11 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corvus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.165 / 3.5827Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.